MDM2 and B-cell chronic lymphocytic leukemia: This is consistent with evidence of a low level of p53 stabilization without activation of downstream protein MDM2 in TP53WT (without del17p) but SF3B1MUT CLL primary samples treated with increasing concentrations of RG7388 (Figure 4A,E).